Report : Middle East & Africa Intradermal Injections Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Method (Normal Sized Needle, Short Needle, and Without Needle), Application (Tuberculin Skin Test, Allergy Test, Local Aesthetics, and Others), and End User (Hospitals, Diagnostic Laboratories, Academics and Research Institutes, and Others)

At 10.2% CAGR, the Middle East & Africa Intradermal Injection Market is speculated to be worth US$ 302.27 million by 2028, says Business Market Insights         

According to the Insight Partners’ research, the Middle East & Africa intradermal injection market was valued at US$ 153.37 million in 2021 and is expected to reach US$ 302.27 million by 2028, registering an annual growth rate of 10.2% from 2021 to 2028.Increasing incidences of diseases and increasing intradermal vaccination are the critical factors attributed to the market expansion.                

During the past few years, the incidence of several communicable and non-communicable diseases has increased exponentially, which is mainly due to the unhealthy lifestyle of modern world. Smoking, infections, and genetic factors can cause serious respiratory complications, cardiovascular disorders, and bacterial and viral infections etc. are a few medical conditions exerting a huge burden on the public healthcare system in various countries. The increasing cases of cancer, tuberculosis and other allergies are expected to act as major drivers for the rapid growth of this segment. As per the data of WHO, about 10 million cases of tuberculosis are observed every year and all of them are diagnosed using tuberculin skin test involving the use of intradermal injection. Along with this, several studies concluded that the intradermal injection could improve the uptake of various cancers and immunological drugs while it can also be used to deliver the gene therapies. Further, continuously increasing cases of COVID19 is also indicating towards the future potential of this segment as various intradermal preparations are under investigation and about to get approved in near future. As the regional population is increasing continuously, the number of cases will also increase in near future, which ultimately increases the demand of intradermal injection. Further, the novel intradermal injection devices such as Tropis ID of Pharmajet shows prominent results in delivering various drugs for targeting a wide range of diseases and expands the therapeutic area of the intradermal products.

On the contrary, risks, complications, and dosing limitations associated with intradermal injections hurdles the growth of Middle East & Africa intradermal injection market. 

  • Based on method, the Middle East & Africa intradermal injection market is segmented into normal sized needles, short needle, and without needle. The normal sized needles segment held 41.1%market share in 2021, amassing US$ 63.04 million. It is projected to garner US$ 119.79 million by 2028 to expand at 9.6% CAGR during 2021–2028. The normal sized needles segment is further subsegmented into intradermal microinjection,microneedle arrays,and tattoo devices. The short needle segment is further subsegmented intradermal liquid jet injectors and ballistic intradermal injectors.
  • Based on application, the Middle East & Africa intradermal injection market is segmented into tuberculin skin test, allergy test, local aesthetics, and others. The tuberculin skin test segment held 31.4% market share in 2021, amassing US$ 48.19 million. It is projected to garner US$ 93.43 million by 2028 to expand at 9.9% CAGR during 2021–2028.
  • Based on end user, the Middle East & Africa intradermal injection market is segmented into hospitals, diagnostic laboratories, academics and research institutes, and others. The hospitals segment held 43.1% market share in 2021, amassing US$ 66.06 million. It is projected to garner US$ 131.36 million by 2028 to expand at 10.3% CAGR during 2021–2028.
  • Based on country, the Middle East & Africa intradermal injection market has been categorized into Saudi Arabia, South Africa, UAE, and rest of Middle East & Africa.  Our regional analysis states that Saudi Arabia captured 43.1% market share in 2021. It was assessed at US$ 66.07 million in 2021 and is likely to hit US$ 128.64 million by 2028, exhibiting a CAGR of 10.0% during the forecast period.  

Key players profiles in the Middle East & Africa intradermal injection market report are BD; West Pharmaceutical Services, Inc; Terumo Corporation; Nanopass; PharmaJet; Idevax; Eunsung Global; Crossject; Cardinal Health Inc; and Hindustan Syringes and Medical Devices Ltd among others.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com

Download Free PDF Brochure